Glonghui, October 25 | UBS published a research report, saying that Alibaba Health recently faced industry resistance brought about by weak consumption and tight regulations, so it lowered its revenue forecast for the 2024-26 fiscal year by about 4% to 11%. Revenue during the period is expected to increase by 15%, 19% and 20%, respectively, and the target price was lowered from HK$6.5 to HK$5, maintaining a “neutral” rating. The bank expects the Group's healthcare e-commerce sales growth to slow over the next 6 to 12 months. This is due to earlier demand due to the pandemic last year, weak consumption recovery, and increased government supervision of healthcare and online drug sales. The bank expects the company's revenue to grow at a compound annual rate of 18% from fiscal year 2023 to fiscal year 26 (previously expected 23%). The bank expects that the entire industry is facing various challenges, which will put pressure on the company's revenue growth in the short term.